PMID- 15748543
OWN - NLM
STAT- MEDLINE
DCOM- 20060620
LR  - 20151119
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 11
IP  - 1
DP  - 2005 Mar 1
TI  - Omalizumab: a recombinant humanized monoclonal IgE-blocking antibody.
PG  - 2
AB  - Omalizumab (Xolair) is a recombinant humanized monoclonal antibody that blocks 
      the high-affinity Fc receptor of immunoglobulin E (IgE). It is used to treat 
      patients with moderate-persistent to severe-persistent asthma; patients must be 
      older than 12 years, have a positive skin test to a perennial aeroallergen (e.g., 
      dust mites, cats, dogs, and mold), and be symptomatic with inhaled 
      corticosteroids. Omalizumab has a low incidence of side effects, and it is very 
      expensive. The exact dosage of omalizumab dosage is determined by body weight and 
      pretreatment serum total IgE levels. Omalizumab may have a role in the treatment 
      of atopic dermatitis when IgE plays a causal role.
FAU - Scheinfeld, Noah
AU  - Scheinfeld N
AD  - Department of Dermatology, St Lukes Roosevelt Hospital, USA. 
      Scheinfeld@Earthlink.net
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20050301
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Dermatologic Agents)
RN  - 0 (Interleukins)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Antibodies, Anti-Idiotypic
MH  - Antibodies, Monoclonal/immunology/pharmacology/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Clinical Trials as Topic
MH  - Dermatitis, Atopic/*drug therapy
MH  - Dermatologic Agents/immunology/pharmacology/*therapeutic use
MH  - Humans
MH  - Immunoglobulin E/*drug effects
MH  - Interleukins/immunology
MH  - Omalizumab
RF  - 19
EDAT- 2005/03/08 09:00
MHDA- 2006/06/21 09:00
CRDT- 2005/03/08 09:00
PHST- 2005/03/08 09:00 [pubmed]
PHST- 2006/06/21 09:00 [medline]
PHST- 2005/03/08 09:00 [entrez]
PST - epublish
SO  - Dermatol Online J. 2005 Mar 1;11(1):2.